Drugs repurposing for COVID-19: phase III clinical trial evaluation
Abstract
World Health Organization (WHO) has announced coronavirus disease 2019 (COVID-19) as a global pandemic which is the largest public health crisis in this century. The spread of COVID-19 is still not well-controlled even become global health threat. As new disease, the specific drugs for COVID-19 have not been available, yet. Face of this condition, repurposing existing drugs become the best options in order to meet the urgently need of the effective drugs. In this article, the clinical trial results of some drugs for the treatment of COVID-19 included hydroxychloroquine, chloroquine, lopinavir/ritonavir, remdesivir, oseltamivir, favipiravir, and corticosteroids were reviewed. Hydroxychloroquine, choloquine and lopinavir/ritonavir were shown to be ineffective. Therefore, they were excluded from the list of drugs for the tratment of COVID-19 by WHO and the National Agency of Drug and Food Control of Republic of Indonesia (NCDE NA-DFC RI). Furthermore, NA-DFC RI has issued an emergency use authorization (EUA) for the use of remdesivir and favipiravir for the treatment of COVID-19.
References
Kementrian Kesehatan Republik Indonesia. Situasi terkini perkembangan coronavirus disease19. 4 Januari 2021. Situasi Infeksi Emerging [Internet]. [cited 2021 Jan 4]. Available from: https://infeksiemerging.kemkes.go.id/situasi-infeksi-emerging
Satuan Tugas Penanganan COVID-19. Sebanyak 611.097 Pasien Sembuh COVID-19 di Tahun 2020 [Internet]. [cited 2021 Jan 4]. Available from: https://COVID19.go.id/berita/sebanyak-611097-pasien-sembuh-COVID-19-di-tahun-2020
World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. [cited 2021 Jan 4]. Available from: https://COVID19.who.int/table
Del Rio C, Malani P. Translating science on COVID-19 to improve clinical care and support the public health response. JAMA 2020;323(24):2464-5.
https://doi.org/10.1001/jama.2020.9252
Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ 2020;371:1-6.
https://doi.org/10.1136/bmj.m3862
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 2020;324(8):782-93.
https://doi.org/10.1001/jama.2020.12839
McIntosh K, Hirsch MS, Bloom A. Coronavirus disease 2019 (COVID-19): Epidemiology, virology, and prevention [Internet]. Dec 2020 [cited 2021 Jan 9]. Available from: https://www.uptodate.com/contents/coronavirus-disease-2019-COVID-19-epidemiology-virology-and-prevention
BPOM RI. Informatorium obat COVID-19 di Indonesia. Jakarta: BPOM RI, 2020: 206.
World Health Organization. Landscape analysis of therapeutics as 21st March 2020 [Internet]. 2020. [cited 2021 Jan 9]: 1-49 p. Available from: https://www.who.int/blueprint/priority-diseases/key action/Table_of_therapeutics_ Appendix_17022020.pdf
World Health Organization. Off-label use of medicines for COVID-19. WHO [Internet]. 2020;March [cited 2021 Jan 9]:3-5. Available from: https://www.who.int/news-room/commentaries/detail/off-label-use-of-medicines-for-COVID-19
US Food and Drug Administration. Development & approval process drugs [Internet]. [cited 2021 Jan 8]. Available from: https://www.fda.gov/drugs/development-approval-process-drugs#:~:text=FDA approval of a drug, risks for the intended population.
CRB. The basics and the process of drug approval [Internet]. [cited 2021 Jan 10]. Available from: https://www.crbgroup.com/insights/pharmaceuticals/drug-approval-process
BPOM RI. Pedoman pelayanan publik di bidang obat dalam kondisi pandemi COVID-19. Jakarta: BPOM RI, 2020: 1-48.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med 2020;382(24):2327-36.
https://doi.org/10.1056/NEJMoa2007016
WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19 - Interim WHO solidarity trial results. N Engl J Med 2020; NEJMoa2023184.
PREVAIL II Writing Group: Multi-National PREVAIL II Study Team. A randomized, controlled trial of ZMapp for ebola virus infection. N Engl J Med 2016; 375(15):1448-56.
https://doi.org/10.1056/NEJMoa1604330
Sorbello A, Jones SC, Carter W, Struble K, Boucher R, Truffa M, et al. Emergency use authorization for intravenous peramivir: Evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza a virus. Clin Infect Dis 2012; 55(1):1-7.
https://doi.org/10.1093/cid/cis351
Pundi K, Perino AC, Harrington RA, Krumholz HM, Turakhia MP. Characteristics and strength of evidence of COVID-19 studies registered on clinicaltrials.gov. JAMA Intern Med 2020;180(10):1398-400.
https://doi.org/10.1001/jamainternmed.2020.2904
Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AI, Fischer A, et al. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children's hospital in New York City, New York. JAMA Pediatr 2020; 174(10):1-7.
https://doi.org/10.1001/jamapediatrics.2020.2430
Vinetz JM. Lack of efficacy of hydroxychloroquine in COVID-19. BMJ 2020; 369:1-2.
https://doi.org/10.1136/bmj.m2018
RC Group. Effect of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 2020; 383(21):2030-40.
https://doi.org/10.1056/NEJMoa2022926
Chen CP, Lin YC, Chen TC, Tseng TY, Wong HL, Kuo CY, et al. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). PLoS One 2020;15:1-14.
https://doi.org/10.1371/journal.pone.0242763
Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020.03.22.20040758
https://doi.org/10.1101/2020.03.22.20040758
Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19 : A Randomized Trial. Ann Intern Med 2020;173(8):623-31.
https://doi.org/10.7326/M20-4207
Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial. BMJ 2020; 369:1-11.
https://doi.org/10.1136/bmj.m1849
Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without Azithromycin in mild-to-moderate COVID-19. N Engl J Med 2020; 383(21):2041-52.
https://doi.org/10.1056/NEJMoa2019014
Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Ritonavir versus Nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346(26):2039-46.
https://doi.org/10.1056/NEJMoa012354.
Levin B, Thompson JL. A trial of lopinavir-ritonavir in COVID-19. N Engl J Med 2020; 382(21):e68.
https://doi.org/10.1056/NEJMc2008043
Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, et al. Lopinavir-Ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2020; 396(10259):1345-52.
https://doi.org/10.1016/S0140-6736(20)32013-4
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020;382(19):1787-99.
https://doi.org/10.1056/NEJMoa2001282
Dolin R, Hirsch MS. Remdesivir - An important first step. N Engl J Med 2020;383(19):1886-7.
https://doi.org/10.1056/NEJMe2018715
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med 2020;383(19):1813-26.
https://doi.org/10.1056/NEJMoa2007764
Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of remdesivir vs standard of care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial. JAMA 2020; 324(11):1048-57.
https://doi.org/10.1001/jama.2020.16349
Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. N Engl J Med 2020; 383(19):1827-37.
https://doi.org/10.1056/NEJMoa2015301
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395(10236):1569-78.
https://doi.org/10.1016/S0140-6736(20)31022-9
Dyer O. COVID-19: Remdesivir has little or no impact on survival, WHO trial shows. BMJ 2020; 371: m4057.
https://doi.org/10.1136/bmj.m4057
Lee VJ, Yap J, Cook AR, Chen MI, Tay JK, Tan BH, et al. Oseltamivir ring prophylaxis for containment of 2009 H1N1 Influenza outbreaks. N Engl J Med 2010; 362(23):2166-74.
https://doi.org/10.1056/NEJMoa0908482
Pusat Informasi Obat Nasional, BPOM RI. OSELTAMIVIR [Internet]. [cited 2021 Jan 6]. Available from: http://pionas.pom.go.id/monografi/oseltamivir
Tan Q, Duan L, Ma Y, Wu F, Huang Q, Mao K, et al. Is oseltamivir suitable for fighting against COVID-19: in silico assessment, in vitro and retrospective study. Bioorg Chem 2020; 104: 104257.
https://doi.org/10.1016/j.bioorg.2020.104257
Chen J, Cai Q, Yang M, Liu D, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020; 6(10):1192-8.
https://doi.org/10.1016/j.eng.2020.03.007
Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother 2020; 64(12): e01897-20.
https://doi.org/10.1128/AAC.01897-20
RC Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med 2020; NEJMoa2021436.
https://doi.org/10.1056/NEJMoa2021436.
BPOM RI. Tingkatkan angka kesembuhan dan turunkan angka kematian pasien COVID-19, Badan POM terbitkan izin penggunaan dalam kondisi darurat obat favipiravir dan remdesivir [Internet]. [cited 2021 Jan 5]. Available from: https://www.pom.go.id/new/view/more/pers/565/Tingkatkan-Angka-Kesembuhan-dan-Turunkan-Angka-Kematian-Pasien-COVID-19--Badan-POM-Terbitkan-Izin-Penggunaan-dalam-Kondisi-Darurat-Obat-Favipiravir-dan-Remdesivir.html
Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA 2020;324(13):1307-16.
https://doi.org/10.1001/jama.2020.17021
Corral-Gudino L, Bahamonde A, Arnaiz-revillas F, Gómez-barquero J, Abadía-Otero J, García-Ibarbia C, et al. GLUCOCOVID : A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. medRxiv 2020; preprint. https://doi.org/10.1101/2020.06.17.20133579
